
    
      This study will involve patients and follow the standard "3 + 3"design. KN044 will be
      antimedical intravenously over 30 minutes with planned doses of 0.03, 0.1, 0.3, 1, 3, 6,10
      mg/kg Once every 3 weeks for first 4 doses, then every 3, or 6, or 12 weeks for up to 1 year
      if no intolerable toxicities occur and per agreement with investigator antimedical monitor
      based on emerging data.
    
  